Today's Date: September 25, 2023
Shift4 Partners with Give Lively to Offer Powerful Fundraising Solution to Nonprofits   •   Intel Editorial: Intel Addresses Semiconductor Workforce Shortage   •   France Announces €40 Million in New Funding to Education Cannot Wait at Global Citizen Festival   •   A Meyers Manx Collaboration with Artist Sage Vaughn Contributes $200,000 to Arts Education Fundraiser   •   THE BLACK WOMEN'S AGENDA, INC. HOSTS 46TH ANNUAL SYMPOSIUM TOWN HALL & AWARDS LUNCHEON   •   Sixth Annual War Heroes on Water Charity Sportfishing Tournament Kicks Off, Bringing Hope and Healing to Combat-Wounded Veterans   •   Reactive Technologies’ Grid Inertia Measurement Tech to Enable Offshore Wind Rollout in Taiwan   • collaborates with   •   2023 Gangnam Festival to be Held in Gangnam, the Heart of K-pop   •   Guidewire Optimistic About New Direction of California Insurance   •   Wondershare FamiSafe 7.0 safeguarding Children with AI   •   2023 GLOBAL CITIZEN FESTIVAL SEES $240 MILLION COMMITMENT FROM FRANCE AND NORWAY TO COMBAT THE GLOBAL FOOD CRISIS   •   65+ Populations in Upstate NY's 4 Largest Regions Surging, Getting Poorer; AARP NY to Meet with Local Leaders   •   No more oil, gas and coal. Two nation-states join growing bloc of countries calling for a Fossil Fuel Non-Proliferation Treaty   •   Statement by the Prime Minister on Yom Kippur   •   Live Good Inc. Celebrates Diversity and Unity: A Beacon of Progress in the Spirit of Crissy Field, Angel Island and the Buffalo   •   Joint Statement on the Importance of Comprehensive, Multidisciplinary and Collaborative Care for Patients with Peripheral Artery   •   PRAIRIE VIEW A&M UNIVERSITY ANNOUNCES 2023-2024 WRITER-IN-RESIDENCE ATTICA LOCKE   •   Student Entrepreneurs from Yale University Win Prestigious $1 Million 2023 Hult Prize   •   Statement by Minister Khera on Yom Kippur
Bookmark and Share

Aviceda Announces Dosing of First Patient With AVD-104, a Novel Glyco-Mimetic Nanoparticle for the Treatment of Geographic Atrop

CAMBRIDGE, Mass. , June 01 /Businesswire/ - Aviceda Therapeutics, a private clinical-stage biotech company focused on developing next generation immuno-modulators by harnessing the power of glycobiology to alleviate chronic, non-resolving inflammation, announced the dosing of its first patient with AVD-104 in its Phase 2 SIGLEC Trial today by Ashkan Abbey, MD of Texas Retina Associates in Dallas. This lead intravitreal asset is a novel glycan-coated nanoparticle, supported by a uniquely strong pre-clinical in vivo efficacy and safety profile, used for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). “I am honored to be the first to dose a new agent that we hope will usher in a generation of safe treatments for GA with better outcomes than were ever possible before,” said Dr. Abbey.

“AVD-104 is a potentially transformative targeted approach for patients with GA due to AMD,” said David Callanan, M.D., Chief Medical Officer of Aviceda. “AVD-104 attacks two fundamental processes in GA by modulating critical inflammatory pathways through the inhibition of retinal macrophage inflammatory activity and repolarization of activated macrophages to their resolution states, and, through inhibition of complement cascade amplification. Based on this dual mechanism and the exquisite selectivity and preclinical potency of AVD-104, we believe it could provide a profound benefit for patients in dire need of new therapies. We have designed our Phase 2 trial to move efficiently through dose escalation and to increase the chances of seeing early signals of clinical activity.”

Tarek Hassan, M.D., Aviceda’ s Chief Development Officer commented, “I am thrilled to get to the clinic with this first-in-class new drug, and its powerful mechanisms of action that focus on converting activated macrophages to their resolution states, as well as inhibiting complement activation, to safely achieve the next level of efficacy in treating GA from AMD. Soon we look to be able to modulate the inflammatory activity of most immune cells with our HALOS™ (High-Affinity Ligands of Siglecs) platform technology and thereby specifically target other therapeutic areas with unmet needs in immunology, fibrosis, neurology, and others.”

Visit (NCT05839041) to learn more about the SIGLEC trial.

About AMD

Age-related macular degeneration (AMD) is a major cause of moderate and severe vision loss in adults over 60 worldwide, currently affecting approximately 11 million people in the United States. Central vision can be prominently, and permanently, reduced such that affected patients can lose their independence and become limited in many basic functions including reading, driving, and recognizing faces. The wet, or neovascular, form of AMD occurs because of abnormal blood vessel growth, bleeding, and scarring that destroys central retinal cells. Approved anti-VEGF therapies have helped control and treat this form. The dry, or non-neovascular, form of AMD is characterized by the development of geographic atrophy (GA) in which there is irreversible progressive destruction of central retinal cells and underlying blood vessels due to chronic inflammation (with over-activated macrophage activity with resultant phagocytosis of retinal and RPE cells) and abnormal complement activation in the retinal photoreceptor, retinal pigment epithelial, and choriocapillaris regions in the back of the eye. Current therapeutics are under development to treat dry AMD by reducing chronic inflammation and inhibiting elements of the complement cascade.

About Aviceda Therapeutics and AVD-104

Aviceda is a private clinical-stage biotechnology company located in Cambridge, MA, with a proprietary HALOS™ nanotechnology platform and an IND-cleared ophthalmic lead product for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). AVD-104 is an intravitreal nanoparticle molecule with a unique dual mechanism of action for the treatment of GA through its modulation of critical inflammatory pathways: 1) Direct inhibition of the activity of damaging phagocytic macrophages and repolarization of activated macrophages to their resolution state, and 2) inhibition of complement cascade amplification. AVD-104 has demonstrated robust in-vitro/vivo efficacy with inhibition of both inflammatory & complement pathways and the potential for every 3- to 6-month dosing. Outstanding safety has been demonstrated in multiple animal models, including non-human primates, in which no signs of intraocular inflammation were seen. In addition, AVD-104 has demonstrated anti-neovascular activity equivalent to that of aflibercept (Eylea) in a well-established ocular CNV model. SIGLEC Phase 2/3 clinical trial is currently enrolling for GA.

Along with AVD-104, Aviceda has a broad pipeline of products in development in ophthalmology and multiple other therapeutic areas, including neurology, oncology, fibrosis, and immunology.

Learn more about Aviceda Therapeutics.

STORY TAGS: Product/Service, Science, Biotechnology, Nanotechnology, Research, Pharmaceutical, Health, Technology, Clinical Trials, United States, North America, Massachusetts,


White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News